Histone deacetylases, as a new class of anticancer targets, could maintain homeostasis by
catalyzing histone deacetylation and play important roles in regulating the expression of …

Angiogenesis, the formation of new blood vessels from the existing vasculature, is pivotal in
the migration, growth, and differentiation of endothelial cells in normal physiological …

Vascular endothelial growth factors (VEGFs) are the key regulators of vasculogenesis in
normal and oncological development. VEGF-A is the most studied angiogenic factor …

Background: VEGFR-2 is one of the most effective targets in cancer treatment. Aim: The
design and semi-synthesis of new theobromine derivatives as potential VEGFR-2 inhibitors …

The goal of the current study was to prepare two new homologous series of N, N′-
diarylurea and N, N′-diarylthiourea derivatives to investigate the therapeutic effects of …

Considering the fundamental role of protein kinases in the mechanism of protein
phosphorylation in critical cellular processes, their dysregulation, especially in cancers, has …

Multitarget anticancer drugs are more superior than single target drugs regarding patient
compliance, drug adverse effects, drug-drug interactions, drug resistance as well as …

ABSTRACT “A journey of mixed emotions” is a quote that best describes the progress chart
of vascular endothelial growth factor receptor (VEGFR) inhibitors as cancer therapeutics in …

Acquired drug resistance poses a challenge for single-target FGFR inhibitors, leading to the
development of dual-or multi-target FGFR inhibitors. Sulfatinib is a multi-target kinase …

VEGFR, a receptor tyrosine kinase inhibitor (TKI), is an important regulatory factor that
promotes angiogenesis and vascular permeability. It plays a significant role in processes …